certolizumab pegol (Cimzia®)

Reference No. 1713

Publication date:

31/10/2014

Appraisal information

certolizumab pegol (Cimzia®) 200 mg solution for injection

Company:	UCB Pharma Ltd
BNF category:	Musculoskeletal and joint diseases
NMG meeting date:	10/09/2014
AWMSG meeting date:	08/10/2014

Submission Type:	Full Submission
Status:	Superseded
Advice No:	3214
Ministerial ratification:	30/10/2014

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA445) NICE GUIDANCE ISSUED MAY 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation (FAR)

Download

certolizumab pegol (Cimzia) 1713 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

certolizumab pegol (Cimzia) 1713 ASAR

Clinical Expert (CE) Summary

Download

certolizumab pegol (Cimzia) 1713 CE summary